Answers are grounded in this paper and cite their sources.
Case report highlights visual impairment risk from continuing fingolimod after macular edema development, suggesting caution.
Fingolimod is the first effective oral agent in widespread use for relapsing-remitting multiple sclerosis (MS), but it can cause macular edema (ME) as an uncommon complication. ME may be mild and asymptomatic, but it can also produce visual impairment. The mechanism of fingolimod-associated ME (FAME) is thought to be through sphingosine-1-phosphate receptor antagonism, affecting endothelial integrity and increasing the risk of microvascular leaks.1
No takes yet. Share an insight, caveat, or question.
Li et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: